Versant Ventures

Type

Venture Capital

Status

Active

Location

San Francisco, United States

Total investments

379

Average round size

34M

Portfolio companies

181

Rounds per year

15.16

Lead investments

57

Follow on index

0.52

Exits

90

Stages of investment
Private EquityEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

In 1999 was created Versant Ventures, which is appeared as VC. The main office of represented VC is situated in the Menlo Park. The fund was located in North America if to be more exact in United States.

The current fund was established by Barbara Lubash, Brian Atwood, Donald B. Milder, Rebecca Robertson, Samuel Colella, William Link. Besides them, we counted 13 critical employees of this fund in our database.

Speaking about the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations. The average startup value when the investment from Versant Ventures is 50-100 millions dollars. The important activity for fund was in 2008. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in 13-24 deals every year. This Versant Ventures works on 5 percentage points less the average amount of lead investments comparing to the other organizations. The top amount of exits for fund were in 2018.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Versant Ventures, startups are often financed by OrbiMed, Investor Growth Capital Limited, Frazier Healthcare Partners. The meaningful sponsors for the fund in investment in the same round are Pequot Capital, Novartis Venture Fund, Kleiner Perkins. In the next rounds fund is usually obtained by Kleiner Perkins, Novartis Venture Fund, Abingworth.

Among the most popular portfolio startups of the fund, we may highlight Audentes Therapeutics, Pharmion, Kythera Biopharmaceuticals. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. The fund has exact preference in some founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. Among the most popular fund investment industries, there are Medical Device, Life Science.

Show more

Investor highlights

Industry focus
HealthcareBiotech/Life SciencesMedtech
Geo focus
Generalist

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Last fund

Fund size
USD 560000000
Fund raised date
2021-04-21

Analytics

Total investments
379
Lead investments
57
Exits
90
Rounds per year
15.16
Follow on index
0.52
Investments by industry
  • Health Care (267)
  • Biotechnology (260)
  • Medical (144)
  • Medical Device (121)
  • Therapeutics (94)
  • Show 50 more
Investments by region
  • United States (333)
  • Switzerland (25)
  • Canada (6)
  • Germany (2)
  • Sweden (2)
  • Show 5 more
Peak activity year
2008
Number of Unicorns
4
Number of Decacorns
4
Number of Minotaurs
3

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
14
Avg. valuation at time of investment
113M
Group Appearance index
0.94
Avg. company exit year
9
Avg. multiplicator
3.04
Strategy success index
1.00

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Abdera Therapeutics 01 Jan 2022 Biotechnology, Health Care, Health Diagnostics, Life Science Early Stage Venture British Columbia, Vancouver, Canada
Bright Peak Therapeutics 11 Jun 2024 Biotechnology, Therapeutics Late Stage Venture 90M Switzerland, Basel-City, Basel

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.